CHICAGO, May 31, 2026 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical study of NXL-004 for recurrent malignant glioma as Rapid ...
The Wabash River RDA region has been awarded $20 million in READI 1.0 funding and $10 million in READI 2.0 funding. The area ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results